key: cord-0962932-z6v33a9l
authors: Nachman, Dean; Rahamim, Eldad; Kolben, Yotam; Mengesha, Bethlehem; Elbaz-Greener, Gabby; Amir, Offer; Asleh, Rabea
title: In Search of Clinical Impact: Advanced Monitoring Technologies in Daily Heart Failure Care
date: 2021-10-13
journal: J Clin Med
DOI: 10.3390/jcm10204692
sha: dc7507da5ba31e543877184df8909b4e4ab935a2
doc_id: 962932
cord_uid: z6v33a9l

Despite significant advances in the management of heart failure (HF), further improvement in the outcome of this chronic and progressive disease is still considered a major unmet need. Recurrent hospitalizations due to decompensated HF frequently occur, resulting in increased morbidity and mortality rates. Past attempts at early detection of clinical deterioration were mainly based on monitoring of signs and symptoms of HF exacerbation, which have mostly given disappointing results. Extensive research of the pathophysiology of HF decompensation has indicated that hemodynamic alterations start days prior to clinical manifestation. Novel technologies aim to monitor these minute hemodynamic changes, allowing time for therapeutic interventions to prevent hemodynamic derangement and HF exacerbation. The latest noticeable advancements include assessment of lung fluid volume, wearable devices with integrated sensors, and microelectromechanical systems-based implantable devices for continuous measurement of cardiac filling pressures. This manuscript will review the rationale for monitoring HF patients and discuss previous and ongoing attempts to develop clinically meaningful monitoring devices to improve daily HF health care, with particular emphasis on the recent advances and clinical trials relevant to this evolving field.

Heart failure (HF) is a common clinical syndrome with detrimental effects at the individual patient and society levels [1, 2] . Overall, 2.2% of US adults or nearly 6.2 million individuals suffer from HF, imposing a significant yearly financial burden estimated at 30.7 billion US dollars in 2012, and projected to more than double by 2030 [3] . The prevalence of HF is expected to continuously grow due to medical and societal developments [3] . First, HF is rising as the population ages, reaching more than 12% in older adults above the age of 80 [4] . Second, the improvement in treatments of HF has led to lower mortality rates, leaving more patients in need of chronic care [5] . Third, the rise in obesity and metabolic syndrome incidence is another contributor to the increased prevalence of HF cases [3, [6] [7] [8] . Recently, advances in HF drug and device therapies have brought about impactful achievements to the field, yet a quarter of patients will endure considerable symptoms, hospitalizations, and mortality, despite optimal medical treatment. Consequently, additional approaches to further improve the management of HF are essential [6, 9, 10] .

HF is characterized by a progressive course of disease accompanied by recurrent exacerbations leading to high hospitalization and rehospitalization rates, which account Figure 1. Pathophysiologic cascade of heart failure decompensation. Normal cardiac filling pressures and interstitial fluid is noted when heart failure is compensated. Elevated cardiac filling pressures and interstitial fluid can be noticed prior to symptomatic compensated heart failure. (A): Elevated cardiac filling pressures can be monitored using implantable pressure sensors. (B): Interstitial fluid accumulation can be monitored using bioimpedance or remote dielectric sensing and electronic internet connected scales can be used for monitoring weight. (C): Symptoms can be monitored when overt decompensated heart failure ensues. RAAS: renin angiotensin aldosterone system; SNS: sympathetic nervous system. HF: heart failure. Because many conservative monitoring modalities focused on detecting outputs late in the pathophysiological cascade of ADHF have shown conflicting results, it has been suggested that focusing on physiological signals related to earlier alterations may give better results [26] . Therefore, this article aims to review the most recent advances and future perspectives regarding this evolving field of HF monitoring.

The fluid content range in the lungs is 20 to 35% in normal conditions, above which pulmonary edema may occur [23] . Residual pulmonary congestion at the time of discharge after hospitalization for ADHF is a strong predictor of rehospitalization [39] . Pathophysiologic cascade of heart failure decompensation. Normal cardiac filling pressures and interstitial fluid is noted when heart failure is compensated. Elevated cardiac filling pressures and interstitial fluid can be noticed prior to symptomatic compensated heart failure. (A): Elevated cardiac filling pressures can be monitored using implantable pressure sensors. (B): Interstitial fluid accumulation can be monitored using bioimpedance or remote dielectric sensing and electronic internet connected scales can be used for monitoring weight. (C): Symptoms can be monitored when overt decompensated heart failure ensues. RAAS: renin angiotensin aldosterone system; SNS: sympathetic nervous system. HF: heart failure.

The fluid content range in the lungs is 20 to 35% in normal conditions, above which pulmonary edema may occur [23] . Residual pulmonary congestion at the time of discharge after hospitalization for ADHF is a strong predictor of rehospitalization [39] . Pulmonary congestion develops prior to clinical evidence of ADHF (Figure 1 ), thus making it an attractive target for monitoring by several non-invasive technologies.

Impedance techniques in lung water measurements are based on the principle that air and water have different resistance. When water fills the lungs, conductance increases and impedance decreases [40] [41] [42] [43] . Lung impedance (LI) monitoring using Edema-Guard monitor (CardioSet Company Ltd., Tel Aviv, Israel) once a month at ambulatory clinic visits demonstrated decreased HF hospitalization and mortality rate in a randomized controlled trial involving 256 HF patients [44] . Moreover, as measured by LI during HF hospitalization, the improvement in pulmonary fluid volume was predictive of lower readmission rate and demonstrated a better correlation than other clinical measures, such as N-terminal pro-brain natriuretic peptide (NT pro-BNP) or weight [45] [46] [47] .

The CoVa™ Monitoring System (toSense™, Inc. San Diego, CA, USA) is a wearable necklace-shaped device that monitors electrocardiography (ECG) and calculates stroke volume, cardiac output, and thoracic fluid index (TFI) using chest bioimpedance. In a pilot study to predict HF events, 20 patients with New York Heart Association class I-IV HF symptoms underwent daily home monitoring with The CoVa™ Monitoring System. The TFI volatility, defined as the standard deviation of the TFI determined over five days divided by the average TFI over the same 5-day period, was recorded. This study showed an increase of ≥40% in TFI volatility before 100% of the HF events and an 8% reduction in stroke volume before 60% of ADHF events. These findings suggest that a multisensory system has the potential to predict HF hospitalizations [48] .

The Remote Dielectric Sensing (ReDS) vest (Sensible Medical Innovations Ltd., Netanya, Israel), measures the lung fluid content using a focused electromagnetic beam similar to radar technology ( Figure 2 ). When compared to right heart catheterization in HF patients, readings of >34% fluid content were highly correlated to pulmonary capillary wedge pressure >18 mmHg (area under the curve (AUC) of 0.848, a sensitivity of 90.7%, and a specificity of 77.1%) [49] . Furthermore, results from 24 patients hospitalized for ADHF showed a correlation between the reduction in ReDS values and reduced pulmonary congestions and net fluid balance [50] . In another study, including 47 patients hospitalized for HF, hospitalization rates before and after the index hospitalization were compared without and with the use of ReDS vest, showing a significant reduction in HF readmissions with ReDS vest technology [51] . Additionally, preliminary results from a multicenter trial randomizing 268 patients to monitoring-guided or standard medical therapy following ADHF hospitalization demonstrated a 48% (95% CI: 31-87%, p = 0.01) reduction in 9 months rehospitalization in the ambulatory ReDS monitoring group [52] .

Pulmonary congestion develops prior to clinical evidence of ADHF (Figure 1 ), thus making it an attractive target for monitoring by several non-invasive technologies.

Impedance techniques in lung water measurements are based on the principle that air and water have different resistance. When water fills the lungs, conductance increases and impedance decreases [40] [41] [42] [43] . Lung impedance (LI) monitoring using Edema-Guard monitor (CardioSet Company Ltd., Tel Aviv, Israel) once a month at ambulatory clinic visits demonstrated decreased HF hospitalization and mortality rate in a randomized controlled trial involving 256 HF patients [44] . Moreover, as measured by LI during HF hospitalization, the improvement in pulmonary fluid volume was predictive of lower readmission rate and demonstrated a better correlation than other clinical measures, such as N-terminal pro-brain natriuretic peptide (NT pro-BNP) or weight [45] [46] [47] .

The CoVa™ Monitoring System (toSense™, Inc. San Diego, CA, USA) is a wearable necklace-shaped device that monitors electrocardiography (ECG) and calculates stroke volume, cardiac output, and thoracic fluid index (TFI) using chest bioimpedance. In a pilot study to predict HF events, 20 patients with New York Heart Association class I-IV HF symptoms underwent daily home monitoring with The CoVa™ Monitoring System. The TFI volatility, defined as the standard deviation of the TFI determined over five days divided by the average TFI over the same 5-day period, was recorded. This study showed an increase of ≥40% in TFI volatility before 100% of the HF events and an 8% reduction in stroke volume before 60% of ADHF events. These findings suggest that a multisensory system has the potential to predict HF hospitalizations [48] .

The Remote Dielectric Sensing (ReDS) vest (Sensible Medical Innovations Ltd., Netanya, Israel), measures the lung fluid content using a focused electromagnetic beam similar to radar technology ( Figure 2 ). When compared to right heart catheterization in HF patients, readings of >34% fluid content were highly correlated to pulmonary capillary wedge pressure >18 mmHg (area under the curve (AUC) of 0.848, a sensitivity of 90.7%, and a specificity of 77.1%) [49] . Furthermore, results from 24 patients hospitalized for ADHF showed a correlation between the reduction in ReDS values and reduced pulmonary congestions and net fluid balance [50] . In another study, including 47 patients hospitalized for HF, hospitalization rates before and after the index hospitalization were compared without and with the use of ReDS vest, showing a significant reduction in HF readmissions with ReDS vest technology [51] . Additionally, preliminary results from a multicenter trial randomizing 268 patients to monitoring-guided or standard medical therapy following ADHF hospitalization demonstrated a 48% (95% CI: 31-87%, p = 0.01) reduction in 9 months rehospitalization in the ambulatory ReDS monitoring group [52] . 

Whole-body bioimpedance (WBBI) allows the non-invasive measurement of body composition for the assessment of various clinical conditions. This technology works by sending a small electrical current throughout the entire body and measuring its impedance. WBBI was first introduced by Hoofer then revised by Nyboer and validated by Lukaski [53] [54] [55] [56] [57] before it was utilized in cardiology [58] [59] [60] [61] . The NICaS monitor (NI Medical; Hod-Hasharon, Israel) is a continuous WBBI system characterized by the capability of measuring impedance fluctuations through two electrode-like sensors applied to the lower and upper limbs simultaneously with a three-lead ECG [62] . The system provides real-time data on the patient's cardiovascular function, including heart rate, stroke volume and stroke index, cardiac output, and cardiac index. The system also provides information regarding total peripheral resistance, total body water, and the Granov Goor index, an indicator of left ventricular (LV) function [63] . Several studies comparing cardiac output measurements using the NICaS system with the traditional thermodilution method found a correlation of r = 0.886 − 0.91 and Bland-Altman limits of agreement of −1.06 and 0.68 L/min [62, 64, 65] . The system also detected cardiac index changes during coronary artery bypass grafting operations and has monitored the hemodynamic effects of vasodilator administration in patients suffering from ADHF [62] . In an additional study, the device managed to reliably monitor 46 patients hospitalized for ADHF during an infusion of a novel second-generation nitroxyl donor with inotropic, lusitropic, and vasodilatory effects [66] . Contradicting data come from a study comparing the performance of this device to cardiac magnetic resonance imaging (MRI), showing only moderate correlation to cardiac function with significant variability among patients [67] .

This sensor uses the piezoelectric effect and converts changes in pressure into electrical signals [68] . Vibration is generated inside the chest wall by the heart and lungs, pumping blood and air. EverOn (EarlySense, Ramat Gan, Israel) is a novel under-the-mattress piezoelectric sensor that can sense these subtle physiological vibrations and convert them to an electrical signal ready to be decoded at a control unit [69] . In a single-center study involving 30 HF patients discharged home following hospitalization for HF exacerbation, 640 nights of monitoring were collected and analyzed. The study found patterns that could be unique among patients at risk for readmission due to HF exacerbation. For example, respiratory rate was a significant risk factor for HF readmission [70] .

We increasingly observe inflation in complex wearable monitoring devices [71] . Numerous consumer smartwatches incorporate medical-grade sensors such as ECG and pulse oximeters, enabling early detection of common medical conditions such as atrial fibrillation [72] [73] [74] . ECG patches allow long-term ambulatory monitoring of arrhythmia [75] . In addition, continuous blood pressure monitoring is available at a wristwatch configuration using cuff-based or pulse wave transit time technologies [76, 77] .

The LINK-HF (Multisensor Non-invasive Remote Monitoring for Prediction of Heart Failure Exacerbation) multicenter study has examined the accuracy of a wearable multisensor remote monitoring patch (Vital Connect, San Jose, CA, USA) for the prediction of ADHF rehospitalization. This disposable patch is attached to the chest and is able to collect continuous ECG, skin impedance, body temperature, and activity level data. Utilizing artificial intelligence to generate a personalized baseline model-based alerts, the system forecasted ADHF with a 76% to 88% sensitivity and an 85% specificity [78] . This study emphasizes the power of personalized data collection and analysis as well as the clinical usefulness of a multiparameter approach that has become available with the introduction of these wearable devices in clinical practice.

Cardiac implanted electronic devices (CIEDs) are indicated in numerous HF patients. Alongside the competence to monitor rhythm disturbances and sleep-disordered breathing, several studies have examined whether CIED's remote monitoring capabilities could facilitate early warning of ADHF development. In the IN-TIME trial (implant-based multiparameter telemonitoring of patients with heart failure), HF treatment was modified according to home-monitored variations in the electrocardiogram, such as ventricular extrasystoles or tachyarrhythmias, and patient activity level. At one year of follow-up, 63 (18.9%) of 333 monitored patients vs. 90 (27.2%) of 331 in the control group developed the composite outcome of death, HF hospitalization, worsening NYHA class, or worsening self-assessment (OR 0.63, 95% CI: 0.43-0.90, p = 0.013) [79] . However, other studies utilizing CIEDs with similar capabilities have failed or showed mixed results [80] .

A unique feature of selected CIEDs is the capability to perform intrathoracic impedance monitoring, to some extent, similar to the non-invasive devices already described [81, 82] . In the Diagnostic Outcome Trial in Heart Failure (DOT-HF), 335 HF patients implanted with CIEDs capable of impedance monitoring (OptiVol fluid assessment algorithm, Medtronic Inc., Minneapolis, MN, USA) were randomized to active monitoring or no monitoring. Unexpectedly, active monitoring was found to be associated with higher rates of HF hospitalization and without a mortality benefit [83] . It has been proposed that these findings might be explained by having an extremely high sensitivity with low specificity of these CIEDs, leading to overdiagnosis of worsening HF and increased rates of hospitalization for HF [84, 85] . Furthermore, it was suggested that monitoring the complex interplay of HF with a single signal is not sufficient. To overcome these limitations, the HeartLogic algorithm (Boston Scientific, Marlborough, MA, USA) combines multiple pathophysiologydriven parameters into an integrated index, including heart sounds, respiration and heart rate, thoracic impedance, and physical activity. The HeartLogic algorithm was able to detect ADHF events with a sensitivity of 70% with a median lead time of 34 days prior to the event, and small reports also demonstrated improved clinical outcome when HF management was guided by the algorithm [86, 87] .

Notably, previous studies have demonstrated that an increase in filling pressure may precede HF decompensation by three weeks or even more [27] . These findings have accelerated the search for effective and reliable devices that can consistently transmit intracardiac pressure readings to identify filling pressure rise early before clinical deterioration occurs. Two decades ago, an implantable hemodynamic monitoring device implanted in the right ventricle as a pacemaker was introduced. The device recorded various parameters, such as heart rate, right ventricle systolic and diastolic blood pressure, and estimated diastolic pulmonary artery (PA) pressure [88, 89] . This device opened the door for an era of advanced invasive monitoring in the setting of HF.

The CardioMEMS (Abbott, Sylmar, CA, USA) ( Figure 3 ) is a wireless pressure sensor that uses micro-electromechanical systems (MEMS) technology. The device is implanted in the distal PA via a right heart catheterization. It is composed of a coil and a capacitor enveloped by a sealed silica capsule covered by silicone. Changes in PA pressure are detected by the sensor and transmitted to a home-monitoring device. The data are collected by the patient and transferred to the clinic for prompt analysis and adjustment of HF therapies accordingly [90] . The CardioMEMS HF Sensor Allows Monitoring of Pressures to Improve Outcomes in NYHA Functional Class III Heart Failure Patients (CHAMPION) trial has investigated the use of CardioMEMS sensor implanted in the PA. Five hundred and fifty HF patients with NYHA Class III and a previous admission for HF in the prior year were recruited. On top of standard care and after implementing the CardioMEMS sensor in both groups, in the treatment group, physicians could monitor the PA pressure and adjust treatment accordingly, while in the control group, no PA pressure-guided adjustment of treatment was performed. After six months of follow-up, there was a significant reduction in hospitalization for HF in the treatment group (HR 0.72, 95% CI 0.60-0.85, p = 0.0002) compared to the control group. No major complications related to the sensor implantation or any sensing failure were observed. During the entire follow-up period (mean of 15 months), the treatment group had a 37% reduction in HF-related hospitalizations compared with standard care alone [91] . In the open-access period, which followed patients for an additional 13 months, physicians had access to PA pressures for all patients. Patients who were not previously monitored while in the control group had a 48% (HR 0.52 (95% CI: 40-69%; p < 0.0001) reduction in admissions for HF compared with the nonmonitored period [92] . These results were consistent in all patients regardless of the LV ejection fraction or of receiving guideline-directed medical therapy [93, 94] .

To assess the generalizability of the CardioMEMS system, a larger study involving 1200 participants was conducted, with a special focus on subgroup diversity defined by sex, race, and ejection fraction. The rate of HF-related hospitalizations was significantly lower after 12 months of follow-up compared with the year before implantation (0.54 vs. 1.25 events per patient-years, hazard ratio (HR) 0.43 (95% CI: 0.39-0.47; p < 0.0001)). The rate of all-cause hospitalization was also lower following sensor implantation (1.67 vs. 2.28 events per patient-years, HR 0.73 (95% CI: 0.68-0.78), p < 0.0001)). Subgroup analyses including ejection fraction, sex, race, cause of cardiomyopathy, presence/absence of implantable cardiac defibrillator, or cardiac resynchronization therapy found no significant interaction between any of these variables and the prespecified outcomes, indicating consistent benefits on HF hospitalization using the CardioMEMS system in various patient cohorts [95] .

Given these promising results, CardioMEMS was approved by the FDA in 2014 [96] , and real-world data from several retrospective cohort studies demonstrated similar results [97, 98] . In the European Society of Cardiology (ESC) guidelines from 2021, monitoring of PA pressure using a wireless implantable hemodynamic monitoring system (Car-dioMEMS) received a class IIb recommendation for symptomatic patients with HF and a previous HF hospitalization [99] .

The recent 1022 participants, GUIDE-HF (hemodynamic-guided management of HF) trial tested if the benefits of PA monitoring extended beyond NYHA functional class III to The CardioMEMS HF Sensor Allows Monitoring of Pressures to Improve Outcomes in NYHA Functional Class III Heart Failure Patients (CHAMPION) trial has investigated the use of CardioMEMS sensor implanted in the PA. Five hundred and fifty HF patients with NYHA Class III and a previous admission for HF in the prior year were recruited. On top of standard care and after implementing the CardioMEMS sensor in both groups, in the treatment group, physicians could monitor the PA pressure and adjust treatment accordingly, while in the control group, no PA pressure-guided adjustment of treatment was performed. After six months of follow-up, there was a significant reduction in hospitalization for HF in the treatment group (HR 0.72, 95% CI 0.60-0.85, p = 0.0002) compared to the control group. No major complications related to the sensor implantation or any sensing failure were observed. During the entire follow-up period (mean of 15 months), the treatment group had a 37% reduction in HF-related hospitalizations compared with standard care alone [91] . In the open-access period, which followed patients for an additional 13 months, physicians had access to PA pressures for all patients. Patients who were not previously monitored while in the control group had a 48% (HR 0.52 (95% CI: 40-69%; p < 0.0001) reduction in admissions for HF compared with the nonmonitored period [92] . These results were consistent in all patients regardless of the LV ejection fraction or of receiving guideline-directed medical therapy [93, 94] .

To assess the generalizability of the CardioMEMS system, a larger study involving 1200 participants was conducted, with a special focus on subgroup diversity defined by sex, race, and ejection fraction. The rate of HF-related hospitalizations was significantly lower after 12 months of follow-up compared with the year before implantation (0.54 vs. 1.25 events per patient-years, hazard ratio (HR) 0.43 (95% CI: 0.39-0.47; p < 0.0001)). The rate of all-cause hospitalization was also lower following sensor implantation (1.67 vs. 2.28 events per patient-years, HR 0.73 (95% CI: 0.68-0.78), p < 0.0001)). Subgroup analyses including ejection fraction, sex, race, cause of cardiomyopathy, presence/absence of implantable cardiac defibrillator, or cardiac resynchronization therapy found no significant interaction between any of these variables and the prespecified outcomes, indicating consistent benefits on HF hospitalization using the CardioMEMS system in various patient cohorts [95] .

Given these promising results, CardioMEMS was approved by the FDA in 2014 [96] , and real-world data from several retrospective cohort studies demonstrated similar results [97, 98] . In the European Society of Cardiology (ESC) guidelines from 2021, monitoring of PA pressure using a wireless implantable hemodynamic monitoring system (CardioMEMS) received a class IIb recommendation for symptomatic patients with HF and a previous HF hospitalization [99] .

The recent 1022 participants, GUIDE-HF (hemodynamic-guided management of HF) trial tested if the benefits of PA monitoring extended beyond NYHA functional class III to patients with NYHA Functional class II and IV. The primary endpoint of all-cause mortality and HF hospitalization or unplanned hospital visit was not met in the hemodynamic-guided management compared to controls (HR 0·88, 95% CI 0·74-1·05; p = 0·16). Importantly, the trial was conducted during the COVID-19 pandemic and prespecified COVID-19 impact analysis found significant improvement in the treatment group prior to the pandemic (HR 0·81, 95% CI 0·66-1·00; p = 0·049) [100] .

The Cordella System is another wireless PA pressure sensor. In one study, the Cordella device was implanted in 30 patients without complications or sensor failure. At 90 days, there was a mean difference of 2.7 mmHg between the Cordella sensor and Swan-Gantz catheter measurements (Cordella Sensor: 22.5 ± 11.8 mmHg; Swan-Ganz catheter: 25.2 ± 8.5 mmHg) [101] .

Whereas CardioMEMS and other PA sensors measure right-sided pressures, left-side filling pressure measurements may provide additional important information regarding the patient's tendency for pulmonary congestion. In animal models, an increase in left atrial (LA) pressure significantly correlated with pulmonary congestion, and reversal of pressure elevation resulted in normalization of lung permeability. In addition, many factors contribute to a mismatch between PA and LA pressure, including elevated pulmonary vascular resistance, advanced HF, acute HF, and pulmonary hypertension [26] . These data suggest that PA pressure measurements may be inaccurate in estimating LV filling pressure.

The HeartPOD (Savacor Inc., Los Angeles, CA, USA) is a system that allowed direct LA pressure using an implantable sensor lead connected to a subcutaneous module. The sensor was implanted in the LA transvenously through the interatrial septum [102] . In a large randomized controlled trial examining the safety and efficacy of the HeartPOD system in patients with NYHA class III HF symptoms, patients' enrollment stopped early due to excess implant-related complications [103] . Preliminary results failed to show a net clinical benefit using this device. However, positive results were noted when retrospectively analyzing the CHAMPION trial endpoints of HF-related hospitalizations, thus leaving hope for LA pressure measurement as an optional tool for effective HF monitoring [104] .

A novel LA pressure sensor that is currently being investigated is the V-LAP system (Vectorious Medical Technologies, Tel Aviv, Israel). The V-LAP system is a wireless sensor that uses a MEMS pressure transducer and is implanted in the interatrial septum under angiographic and echocardiographic guidance (Figure 4) . In preclinical phases, the V-LAP system was implanted in 10 ovines, and its measurements were compared with postcapillary wedge pressure (PCWP) obtained by right heart catheterization at 1, 2, and 3-6 months after implantation. The mean difference was 0.19 ± 2.51 mmHg, and a strong correlation between V-LAP and PCWP measurements was observed, with r = 0.97 [105] . Short reports regarding patients implanted with the V-LAP system have similarly indicated significant correlations between PCWP measurements using right heart catheterization and LA pressure measurements, and when appropriate, clinical responses to an increased dose of diuretics in patients with high pressures measured by V-LAP has been observed [106, 107] . 

Early detection and intervention in HF patients to prevent clinical HF decompensation and subsequent hospitalization may provide significant health and financial advantages. In contrast to previous monitoring methods, novel technologies have been developed to target the initial aspects of the pathophysiological cascade of HF decompensation. Invasive and non-invasive methods have remarkably advanced cardiovascular medicine, taking advantage of recent developments in MEMS, big data, artificial intelligence, and wearable sensors. There is a growing body of evidence supporting a potential clinical benefit from monitoring devices for the management of HF, mainly with PA pressure monitoring. Table 1 summarizes the key clinical trials published recently on different ambulatory heart failure monitoring technologies and their main findings. In the future, alongside further technological advances, appropriate integration of patient monitoring into the clinical workflow will help make the most of these exciting devices. 

Early detection and intervention in HF patients to prevent clinical HF decompensation and subsequent hospitalization may provide significant health and financial advantages. In contrast to previous monitoring methods, novel technologies have been developed to target the initial aspects of the pathophysiological cascade of HF decompensation. Invasive and non-invasive methods have remarkably advanced cardiovascular medicine, taking advantage of recent developments in MEMS, big data, artificial intelligence, and wearable sensors. There is a growing body of evidence supporting a potential clinical benefit from monitoring devices for the management of HF, mainly with PA pressure monitoring. Table  1 summarizes the key clinical trials published recently on different ambulatory heart failure monitoring technologies and their main findings. In the future, alongside further technological advances, appropriate integration of patient monitoring into the clinical workflow will help make the most of these exciting devices. 

Heart failure drug treatment

Heart failure

Forecasting the impact of heart failure in the United States: A policy statement from the

Heart disease and stroke statistics-2012 update: A report from the American Heart Association

Changing incidence and survival for heart failure in a well-defined older population

The annual global economic burden of heart failure

Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes

ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation

Epidemiology of heart failure and long-term follow-up outcomes in a north-African population: Results from the NAtional TUnisian REgistry of Heart Failure (NATURE-HF)

Lifetime costs of medical care after heart failure diagnosis

Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction

Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure

Outcome of heart failure with preserved ejection fraction in a population-based study

Rehospitalizations among patients in the Medicare fee-for-service program

Short-term rehospitalization across the spectrum of age and insurance types in the United States

Who has higher readmission rates for heart failure, and why? Implications for efforts to improve care using financial incentives

Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarc-tion, or Pneumonia

Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study)

A Multidisciplinary Intervention to Prevent the Readmission of Elderly Patients with Congestive Heart Failure

Physical Rehabilitation for Older Patients Hospitalized for Heart Failure

A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare popultion

Transition from chronic compensated to acute decompensated heart failure: Pathophysiological insights obtained from continuous monitoring of intracardiac pressures

Implantable Hemodynamic Monitoring for Heart Failure Patients

Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: New insights from continuous monitoring devices

Hormones and hemodynamics in heart failure

Adverse consequences of high sympathetic nervous activity in the failing human heart

Pathophysiology and clinical evaluation of acute heart failure

Invasive Devices and Sensors for Remote Care of Heart Failure Patients

Loop diuretics for chronic heart failure: A foe in disguise of a friend?

Weight monitoring in patients with severe heart failure (WISH). A randomized controlled trial

TEN-HMS Investigators. Predicting hospitalization due to worsening heart failure using daily weight measurement: Analysis of the Trans-European Network-Home-Care Management System (TEN-HMS) study

Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: The Trans-European Network-Home-Care Management System (TEN-HMS) study

Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): A randomised, controlled, parallel-group, unmasked trial

Feasibility and effectiveness of a multidimensional post-discharge disease management programme for heart failure patients in clinical practice: The HerzMobil Tirol programme

Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure: The Better Effectiveness After Transition-Heart Failure (BEAT-HF) Randomized Clinical Trial

Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure

Bioimpedance monitoring: Better than chest x-ray for predicting abnormal pulmonary fluid? Congest

Transthoracic electric impedance. A clinical guide of pulmonary fluid accumulation in congestive heart failure

Transthoracic admittance plethysmograph for measuring cardiac output

Studies on the effect of controlled volume change on the thoracic electrical impedance

Non-Invasive Lung IMPEDANCE-Guided Preemptive Treatment in Chronic Heart Failure Patients: A Randomized Controlled Trial (IMPEDANCE-HF Trial)

Prediction of readmissions and mortality in patients with heart failure: Lessons from the IMPEDANCE-HF extended trial

In-ternal thoracic impedance monitoring: A novel method for the preclinical detection of acute heart failure

Derivation of baseline lung impedance in chronic heart failure patients: Use for monitoring pulmonary congestion and predicting admissions for decompensation

Predicting heart failure events with home monitoring: Use of a novel, wearable necklace to measure stroke volume, cardiac output and thoracic impedance

Relationship Between Noninvasive Assessment of Lung Fluid Volume and Invasively Measured Cardiac Hemodynamics

A novel approach to monitoring pulmonary congestion in heart failure: Initial animal and clinical experiences using remote dielectric sensing technology

Remote Dielectric Sensing (ReDS™)-Guided Patient Management of Ambulatory Heart Failure Patients Reduces Rehospitalization Rates

Primary Results of the Sensible Medical Innovations Lung Fluid Status Monitor Allows Reducing Readmission Rate of Heart Failure Patients (smile) Trial

The theory and fundamentals of bioimpedance analysis in clinical status monitoring and diagnosis of diseases

Continuous noninvasive real-time monitoring of stroke volume and cardiac output by thoracic electrical bioimpedance

Evolution of bioimpedance: A circuitous journey from estimation of physiological function to assessment of body composition and a return to clinical research

Correlation of whole-body impedance with total body water volume

Electrical impedance plethysmography; a physical and physiologic approach to peripheral vascular study

Development and evaluation of an impedance cardiac output system

Impedance cardiography as a noninvasive means to monitor cardiac function

Physiological correlates of the cardiac thoracic impedance waveform

The Minnesota impedance cardiograph-Theory and applications

Vered, Z. Accurate, noninvasive continuous monitoring of cardiac output by whole-body electrical bioimpedance

Detection of left ventricular systolic dysfunction using a newly developed, laptop based, impedance cardiographic index

Non-invasive measurement of cardiac output during coronary artery bypass grafting

Impedance cardiography for cardiac output estimation: Reliability of wrist-to-ankle electrode configuration

A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction

Do whole body impedance cardiography estimates of left ventricular structure, volumes and function correlate with the gold standard of cardiac magnetic resonance imaging?

Overview of Piezoelectric Biosensors, Immunosensors and DNA Sensors and Their Applications

Simultaneous piezoelectric noninvasive detection of multiple vital signs

Home monitoring of heart failure patients at risk for hospital readmission using a novel under-the-mattress piezoelectric sensor: A preliminary single centre experience

Smart wearable devices in cardiovascular care: Where we are and how to move forward

Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation

Accuracy of Apple Watch for Detection of Atrial Fibrillation

Accuracy of wearable heart rate monitors in cardiac rehabilitation

A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome

The first study comparing a wearable watch-type blood pressure monitor with a conventional ambulatory blood pressure monitor on in-office and out-of-office settings

Comparing blood pressure measurements between a photoplethysmography-based and a standard cuff-based manometry device

Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization: The LINK-HF Multicenter Study. Circ. Heart Fail. 2020, 13, e006513

Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): A randomised controlled trial

Remote management of heart failure using implantable electronic devices

Intrathoracic impedance monitoring in patients with heart failure: Correlation with fluid status and feasibility of early warning preceding hospitalization

Measuring impedance in congestive heart failure: Current options and clinical applications

Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure

Too much information)? Circulation

Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure

A Multisensor Algorithm Predicts Heart Failure Events in Patients With Implanted Devices: Results From the MultiSENSE Study

Clinical and economic impact of HeartLogic™ compared with standard care in heart failure patients

Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: A multicenter, 12-month follow-up study of patients with chronic heart failure

Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: The COMPASS-HF study

Where we are and where can we go?

Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial

CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomised trial

Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction

Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction

Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study

Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice

Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Haemodynamic-guided management of heart failure (GUIDE-HF): A randomised controlled trial

Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: Results of the SIRONA first-in-human study

Direct left atrial pressure monitoring in ambulatory heart failure patients: Initial experience with a new permanent implantable device

Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF)

Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOP-HF Trial

A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience

Experience of remote cardiac care during the COVID-19 pandemic: The V-LAP™ device in advanced heart failure

Intra-cardiac microcomputer allows for innovative telemedicine in chronic heartfailure during coronavirus disease-2019 pandemic: A case report